Wall Street Zen Upgrades Spero Therapeutics (NASDAQ:SPRO) to "Hold"

Wall Street Zen upgraded shares of Spero Therapeutics (NASDAQ:SPRO - Free Report) to a hold rating in a research report report published on Saturday morning.

Spero Therapeutics Trading Down 1.7%

Shares of NASDAQ:SPRO traded down $0.05 during mid-day trading on Friday, reaching $2.88. The stock had a trading volume of 1,012,382 shares, compared to its average volume of 1,172,692. The firm has a 50 day simple moving average of $1.46 and a two-hundred day simple moving average of $1.06. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.06. The firm has a market cap of $161.02 million, a PE ratio of -2.25 and a beta of 1.28.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.30. Spero Therapeutics had a negative net margin of 156.48% and a negative return on equity of 123.50%. The company had revenue of $5.87 million for the quarter, compared to analyst estimates of $11.00 million. On average, equities analysts anticipate that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Institutional Trading of Spero Therapeutics

Several hedge funds have recently bought and sold shares of SPRO. Mackenzie Financial Corp grew its holdings in shares of Spero Therapeutics by 11.4% during the first quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock worth $151,000 after buying an additional 21,472 shares in the last quarter. Three Seasons Wealth LLC bought a new position in shares of Spero Therapeutics during the 4th quarter worth approximately $31,000. XTX Topco Ltd acquired a new stake in shares of Spero Therapeutics in the fourth quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in shares of Spero Therapeutics in the fourth quarter worth $47,000. Finally, Prudential Financial Inc. acquired a new position in Spero Therapeutics during the fourth quarter worth $51,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.